Bile acids bind to multiple receptors, including Takeda G protein-coupled receptor 5 (TGR5) and farnesoid-X-receptors alpha (FXRα). We compared the response of PBMCs to the activation of these receptors in healthy controls and myasthenic patients. We found that TGR5 is a more potent negative regulator of T cell cytokine response than FXRα in both groups. In contrast, TGR5 and FXRα agonists elicit distinct B cell responses in myasthenia compared to controls, specifically on the frequency of IL-6+ B cells and regulatory B cells, as well as IL-10 secretion from PBMCs. We propose that TGR5 is a potential therapeutic target in myasthenia.

中文翻译：

---

胆汁酸受体激动剂对重症肌无力免疫反应的调节

胆汁酸与多种受体结合，包括武田 G 蛋白偶联受体 5 (TGR5) 和法尼醇 X 受体α (FXRα)。我们比较了健康对照和肌无力患者中 PBMC 对这些受体激活的反应。我们发现，在两组中，TGR5 是比 FXRα 更有效的 T 细胞细胞因子反应负调节剂。相比之下，与对照组相比，TGR5 和 FXRα 激动剂在肌无力中引发不同的 B 细胞反应，特别是在 IL-6+ B 细胞和调节性 B 细胞的频率以及 PBMC 分泌 IL-10 方面。我们建议 TGR5 是肌无力的潜在治疗靶点。